BRAF and cutaneous melanoma: In cutaneous melanoma, inhibitors of the BRAF (BRAFi) and MEK (MEKi) kinases (e.g., vemurafenib and cobimetinib) are prototypical of highly effective targeted anti‐cancer drugs (English & Cobb, 2002; Samatar & Poulikakos, 2014).